Methods for administration of taxol
US5621001A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 20, 1995 |
| Grant date | Apr 15, 1997 |
| Priority date | — |
| Expiry date | Nov 20, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Taxol dosages of about 135 mg/m.sup.2 or greater are administered via infusions of less than 6 hours duration; the method makes it possible to provide taxol infusions on an out-patient basis to patients who do not otherwise require hospitalization. In a preferred embodiment, about 135 mg/m.sup.2 of taxol in a cremaphor emulsion is infused over a 3 hour duration, following patient pretreatment with steroids, antihistamines, and H.sub.2 -receptor antagonists sufficient to prevent fatal anaphylactic-like reactions, and preferably sufficient to reduce the occurrence of severe anaphylactic-like reactions in greater than 90% of patients treated. In an alternative embodiment, between 135 mg/m.sup.2 and about 175 mg/m.sup.2 of taxol is provided in a 3-hour infusion, following pretreatment to minimize hypersensitivity responses. A method for rechallenging patients with taxol after episodes of acute hypersensitivity reactions is also disclosed, thus enabling patients to continue taxol therapy who would otherwise be deprived of treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.